Document Detail


Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia.
MedLine Citation:
PMID:  19521678     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To study the mesolimbic dopamine system during expectation and receipt or omission of rewards in partially remitted patients with schizophrenia treated with the atypical antipsychotic olanzapine.
METHODS: We studied 16 patients with a current episode of schizophrenia, all treated with the atypical drug olanzapine, and 16 healthy subjects using functional magnetic resonance imaging. Subjects performed a delayed incentive paradigm with monetary rewards.
RESULTS: During reward expectation, both, patients with schizophrenia and healthy control subjects, showed activation of the ventral striatum and midbrain in the vicinity of the ventral tegmental area. Significant categorical group differences emerged in the anterior cingulate cortex with only healthy controls showing increasing activation with increasing reward. In the patients, activation of this region was inversely correlated with positive symptoms. During outcome, both, patients with schizophrenia and healthy controls, showed activation of the ventral striatum and the mesial prefrontal cortex. Significant categorical group differences emerged in the right ventrolateral prefrontal cortex for the salience contrast with healthy controls showing a U-shaped activation curve, i.e., higher activation for either omission or receipt of reward compared to no reward.
CONCLUSIONS: Our findings partially support the current concept of dopaminergic dysfunction in schizophrenia, suggesting a rather hyperactive mesolimbic dopamine system and reduced prefrontal activation, at least in partially remitted patients treated with atypical antipsychotics.
Authors:
Henrik Walter; Hannes Kammerer; Karel Frasch; Manfred Spitzer; Birgit Abler
Related Documents :
22279338 - Predictors of quality of life of hemodialysis patients in india.
17052898 - Dysfunction of dorsolateral prefrontal cortex in antipsychotic-naïve schizophreniform ...
21055908 - Temporal pole morphology in first-episode schizophrenia patients: clinical correlations.
22705238 - Responsiveness of the motor function measure in neuromuscular diseases.
1734288 - Clinical and eeg features of status epilepticus in comatose patients.
20491018 - Baseline characteristics of patients from poland enrolled in the global registry of pat...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-06-12
Journal Detail:
Title:  Psychopharmacology     Volume:  206     ISSN:  1432-2072     ISO Abbreviation:  Psychopharmacology (Berl.)     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-08-17     Completed Date:  2009-12-29     Revised Date:  2014-03-25    
Medline Journal Info:
Nlm Unique ID:  7608025     Medline TA:  Psychopharmacology (Berl)     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  121-32     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antipsychotic Agents / pharmacology*,  therapeutic use
Basal Ganglia / physiopathology
Benzodiazepines / pharmacology*,  therapeutic use
Dopamine / metabolism*
Female
Gyrus Cinguli / physiopathology
Humans
Magnetic Resonance Imaging
Male
Prefrontal Cortex / physiopathology
Psychomotor Performance / drug effects
Reward*
Schizophrenia / drug therapy,  physiopathology*
Schizophrenic Psychology*
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 12794-10-4/Benzodiazepines; 132539-06-1/olanzapine; VTD58H1Z2X/Dopamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of xenobiotic-metabolizing enzyme gene polymorphisms and interactions with environmental factor...
Next Document:  Two-photon imaging of the immune system: a custom technology platform for high-speed, multicolor tis...